Gene
LRP1B
LRP1B is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (11), Actionable biomarkers (2), Target-disease associations (525), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention LRP1B. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
The yearly numbers
| Year | Publication mentions | Share of that year |
|---|---|---|
| 2023 | 13 of 11,460 | 0.11% |
| 2022 | 4 of 13,598 | 0.03% |
| 2021 | 7 of 15,045 | 0.05% |
| 2020 | 8 of 14,459 | 0.06% |
| 2019 | 4 of 12,159 | 0.03% |
| 2018 | 3 of 11,854 | 0.03% |
| 2017 | 0 of 11,595 | 0.00% |
| 2016 | 4 of 10,983 | 0.04% |
| 2015 | 2 of 11,395 | 0.02% |
| 2014 | 4 of 10,367 | 0.04% |
Showing 10 of 34 years.
Assay-provider ledger (11)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AstraZeneca | Pharma or other | Clinical validationAnalytical validation | 1 | June 01, 2026 |
| Miltenyi Biotec | Reagent supplier | Clinical validationAnalytical validation | 1 | June 01, 2026 |
| Natera | Diagnostic provider | Clinical validationAnalytical validation | 1 | June 01, 2026 |
| ROCHE | Context dependent | Clinical validationAnalytical validation | 1 | June 01, 2026 |
| ABCAM | Reagent supplier | Clinical validationAnalytical validation | 1 | September 30, 2021 |
Showing 5 of 11 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| LRP1B deletion | Liposomal Doxorubicin | responsive | ovarian carcinoma | Cancer Genome Interpreter |
| LRP1B oncogenic mutation | Liposomal Doxorubicin | responsive | ovarian carcinoma | Cancer Genome Interpreter |
Target-disease associations (525)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-methoxytyramine sulfate measurement | measurement | GWAS credible sets |
| 4-guanidinobutanoate measurement | measurement | GWAS credible sets |
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Abdominal pain | phenotype | GWAS credible sets |
Showing 5 of 525 associations.
Vendor sourcing (5)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1676G>A (p.R559H) alteration is located in exon 11 (coding exon 11) of the LRP1B gene. This alteration results from a G to A substitution at nucleotide... | View ClinVar record SCV003528149.2 |
| Central South University | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted without stated criteria (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV004046817.1 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001028733.2 |
| National Health Research Institutes | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV007338607.1 |
| Nationwide Children's Hospital | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Variant has Tier II (potential) clinical significance as a diagnostic inclusion criterion in embryonal rhabdomyosarcoma, based on the following evidence: 1) ... | View ClinVar record SCV007105302.1 |
Trial-cited literature (65)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| A multi-ancestry genome-wide association study identifies novel candidate loci in the RARB gene associated with hypertensive disorders of pregnancy. | HGG advances | 2025 | 1 |
| Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. | BMC medicine | 2024 | 38 |
| Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. | Blood advances | 2024 | 33 |
| Characteristics of gastric cancer around the world. | Critical reviews in oncology/hematology | 2023 | 330 |
| Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | 134 |
Showing 5 of 65 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.C2903R | 1 | 2018 | PMID 30067989 |
| p.E2998K | 1 | 2018 | PMID 29349598 |
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.E2998K | TCGA-SKCM | Nevi and Melanomas; Skin; Connective, subcutaneous and other soft tissues; Lymph nodes; Nasal cavity and middle ear; Vulva; Breast; Bones, joints and articular cartilage of other and unspecified sites; Retroperitoneum and peritoneum; Vagina; Colon; Adrenal gland; Corpus uteri; Other and ill-defined sites; Liver and intrahepatic bile ducts; Anus and anal canal; Spinal cord, cranial nerves, and other parts of central nervous system; Small intestine; Bronchus and lung; Brain; Parotid gland | 1 | 470 | 0.21% | 0.04% to 1.20% |
Literature-extracted relations (5)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Leukemia, Myeloid, Acute | Disease | associate |
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. | 2024 |
| Stomach Neoplasms | Disease | associate |
Characteristics of gastric cancer around the world. | 2023 |
| Insulin Resistance | Disease | associate |
Association studies of novel obesity-related gene variants with quantitative metabolic phenotypes in a population-based sample of 6,039 Danish individuals. | 2012 |
| Adenocarcinoma of Lung | Disease | associate |
Somatic mutations affect key pathways in lung adenocarcinoma. | 2008 |
| Neoplasms | Disease | inhibit |
Somatic mutations affect key pathways in lung adenocarcinoma. | 2008 |
Organizations publishing (117)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 6 | 2016 to 2023 |
| Chinese Academy of Medical Sciences & Peking Union Medical College | Academic | 4 | 2020 to 2024 |
| Memorial Sloan Kettering Cancer Center | Hospital | 4 | 2011 to 2023 |
| Government of the United States of America | Government | 3 | 2013 to 2025 |
| Roche (Switzerland) | Industry | 3 | 2015 to 2022 |
Showing 5 of 117 organizations.
Where LRP1B appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- respiratory or thoracic disease
- urinary system disease
476 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and trial mentions.